Ocugen (OCGN) is a biotechnology firm engaging in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded in 2013, and is headquartered in Malvern, Pennsylvania.
Shares of Ocugen have gains of 71.5% year-to-date, and 12-month gains of 1,655%. I am bearish on OCGN stock. Its fundamentals and valuation do not justify its soaring price.
Furthermore, Ocugen has gained a meme stock status and is more a speculative play rather than a company with solid fundamentals. Click here to read more on this article at The Economist, and stay informed of new changes.
